Chemed (CHE)
(Delayed Data from NYSE)
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$554.39 USD
+5.12 (0.93%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $554.63 +0.24 (0.04%) 7:58 PM ET
1-Strong Buy of 5 1
C Value B Growth A Momentum B VGM
Zacks News
Omnova Solutions and Chemed are Zacks Aggressive Growth Rank Buys
by Brian Bolan
OMN and CHE are profiled as aggressive growth stocks.
Why Is Chemed (CHE) Down 7.8% Since the Last Earnings Report?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Must Add Chemed (CHE) Stock to Your Portfolio
by Zacks Equity Research
Chemed Corporation's (CHE) promising Roto-Rooter revenue outlook as well as an increased bottom-line guidance bode well of the company's future.
Zacks.com featured highlights: Arkema SA, Nutrisystem, Braskem SA, Chemed and SP Plus
by Zacks Equity Research
Zacks.com featured highlights: Arkema SA, Nutrisystem, Braskem SA, Chemed and SP Plus
5 Top Stocks With Solid Net Profit Margin
by Zacks Equity Research
Net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.
Envision Healthcare Hurt by High Debt, Increasing Expenses
by Zacks Equity Research
Envision Healthcare's (EVHC) increasing debt and expenses continue to hurt. Further guidance cut by the company is concerning.
Zacks.com featured highlights: Arkema, Nutrisystem, SYNNEX, Ituran Location and Control and Chemed
by Zacks Equity Research
Zacks.com featured highlights: Arkema, Nutrisystem, SYNNEX, Ituran Location and Control and Chemed
5 Top Stocks with Stellar Net Profit Margin
by Zacks Equity Research
Net profit is the amount a company retains after deducting all costs, interest, depreciation, taxes and other expenses.
Chemed (CHE) Q2 Earnings & Revenues Rise Y/Y, View Revised
by Zacks Equity Research
Chemed (CHE) rides high on Roto-Rooter in second-quarter 2017. An encouraging bottom-line projection raises hopes.
Chemed (CHE) Up 6.4% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Catches Eye: Stock Gains 6.2% in Session
by Zacks Equity Research
Amedisys, Inc. (AMED) moved big last session, as its shares rose over 6% on the day.
Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View
by Zacks Equity Research
Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.
Chemed (CHE): Roto-Rooter Solid, Reimbursement a Concern
by Zacks Equity Research
On Dec 20, we issued an updated research report on Cincinnati, OH-based Chemed Corporation (CHE).
5 Best Healthcare Bargain Stocks to Buy
by David Bartosiak
Healthcare stocks have been beaten down by the market, you need to buy these STAT!